- Home
- RFAI vs VTYX Comparison
RFAI vs VTYX Comparison
Compare RFAI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- VTYX
- Stock Information
- Founded
- RFAI 2024
- VTYX 2018
- Country
- RFAI Singapore
- VTYX United States
- Employees
- RFAI N/A
- VTYX N/A
- Industry
- RFAI
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- RFAI
- VTYX Health Care
- Exchange
- RFAI NYSE
- VTYX Nasdaq
- Market Cap
- RFAI 158.1M
- VTYX 154.9M
- IPO Year
- RFAI 2024
- VTYX 2021
- Fundamental
- Price
- RFAI $10.55
- VTYX $2.77
- Analyst Decision
- RFAI
- VTYX Buy
- Analyst Count
- RFAI 0
- VTYX 4
- Target Price
- RFAI N/A
- VTYX $11.33
- AVG Volume (30 Days)
- RFAI 15.2K
- VTYX 1.9M
- Earning Date
- RFAI 01-01-0001
- VTYX 08-07-2025
- Dividend Yield
- RFAI N/A
- VTYX N/A
- EPS Growth
- RFAI N/A
- VTYX N/A
- EPS
- RFAI 0.32
- VTYX N/A
- Revenue
- RFAI N/A
- VTYX N/A
- Revenue This Year
- RFAI N/A
- VTYX N/A
- Revenue Next Year
- RFAI N/A
- VTYX N/A
- P/E Ratio
- RFAI $33.02
- VTYX N/A
- Revenue Growth
- RFAI N/A
- VTYX N/A
- 52 Week Low
- RFAI $10.05
- VTYX $0.78
- 52 Week High
- RFAI $10.56
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- VTYX 62.76
- Support Level
- RFAI N/A
- VTYX $1.95
- Resistance Level
- RFAI N/A
- VTYX $2.51
- Average True Range (ATR)
- RFAI 0.00
- VTYX 0.17
- MACD
- RFAI 0.00
- VTYX -0.02
- Stochastic Oscillator
- RFAI 0.00
- VTYX 104.37
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.